HRP20171725T1 - FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I NSAR - Google Patents
FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I NSAR Download PDFInfo
- Publication number
- HRP20171725T1 HRP20171725T1 HRP20171725TT HRP20171725T HRP20171725T1 HR P20171725 T1 HRP20171725 T1 HR P20171725T1 HR P20171725T T HRP20171725T T HR P20171725TT HR P20171725 T HRP20171725 T HR P20171725T HR P20171725 T1 HRP20171725 T1 HR P20171725T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmacologically active
- active ingredient
- pain
- pharmaceutical
- dosage form
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 239000002831 pharmacologic agent Substances 0.000 claims 13
- 239000002552 dosage form Substances 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960001259 diclofenac Drugs 0.000 claims 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 229960004420 aceclofenac Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000003040 nociceptive effect Effects 0.000 claims 1
- AJRNYCDWNITGHF-UHFFFAOYSA-N oxametacin Chemical compound CC1=C(CC(=O)NO)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AJRNYCDWNITGHF-UHFFFAOYSA-N 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001107 psychogenic effect Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (14)
1. Farmaceutski pripravak naznačen time da sadrži:
(a) prvi farmakološki aktivni sastojak izabran od spoja prema kemijskoj formuli (I)
[image]
i njihove fiziološki prihvatljive soli, i
(b) drugi farmakološki aktivni sastojak koji je ne-steroidni anti-reumatski lijek odabran iz skupine koja sadrži indometacin, diklofenak, oksametacin, i aceklofenak, te njihove fiziološki prihvatljive soli.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time da je prvi farmakološki aktivni sastojak spoj prema kemijskoj formuli (I)
[image]
3. Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time da je drugi farmakološki aktivni sastojak odabran iz skupine koja sadrži indometacin, diklofenak, te njihove fiziološki prihvatljive soli.
4. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da sadrži prvi i drugi farmakološki aktivni sastojak u takvom masenom omjeru da će nakon davanja pacijentu imati sinergističko terapeutsko djelovanje.
5. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da je relativni omjer mase prvog farmakološki aktivnog sastojka prema drugom farmakološki aktivnom sastojku unutar raspona od 1 : 2 do 1 : 1,000,000.
6. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva naznačen time da je za uporabu za sprječavanje ili liječenje boli.
7. Farmaceutski pripravak prema zahtjevu 6, naznačen time da bol je:
- periferna, središnja ili mišićna skeletna bol; i/ili
- akutna, subakutna ili kronična bol; i/ili
- umjerena do jaka bol; i/ili
- neuropatska ili psihogena ili nociceptivna ili miješana bol; i/ili
- bol u donjem dijelu leđa, visceralna bol ili glavobolja; i/ili
- postoperativna (post-kirurška) bol, rak ili upalna bol.
8. Farmaceutski oblik doziranja naznačen time da sadrži farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva.
9. Farmaceutski oblik doziranja prema zahtjevu 8, naznačen time da sadrži prvi farmakološki aktivni sastojak u dozi od 10 do 1,200 µg.
10. Farmaceutski oblik doziranja prema zahtjevu 8 ili 9, naznačen time da sadrži drugi farmakološki aktivni sastojak u dozi od 10 do 1,000 mg.
11. Farmaceutski oblik doziranja prema bilo kojem od zahtjeva 8 do 10, naznačen time da je doziranje prvog farmakološki aktivnog sastojka u rasponu od 1:20 do 20:1 količine koja je ekvivalentno djelotvorna doziranju drugog farmakološki aktivnog sastojka.
12. Farmaceutski oblik doziranja prema bilo kojem od zahtjeva 8 do 11, naznačen time da je za oralnu, intravensku, intraperitonealnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, potkožnu ili rektalnu primjenu.
13. Komplet koji sadrži prvi farmaceutski oblik doziranja koji sadrži prvi farmakološki aktivni sastojak kako je definiran u zahtjevu 1 ili 2, i drugi farmaceutski oblik doziranja koji sadrži drugi farmakološki aktivni sastojak kako je definiran u patentnom zahtjevu 1 ili 3.
14. Komplet prema zahtjevu 13, naznačen time da su prvi i drugi farmaceutski oblik doziranja prilagođeni za istovremenu ili uzastopnu primjenu, bilo istim ili različitim putem primjene.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12003895 | 2012-05-18 | ||
| PCT/EP2013/001470 WO2013170971A1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar |
| EP13725072.6A EP2849747B1 (en) | 2012-05-18 | 2013-05-16 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171725T1 true HRP20171725T1 (hr) | 2017-12-29 |
Family
ID=48520892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171725TT HRP20171725T1 (hr) | 2012-05-18 | 2017-11-10 | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I NSAR |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8912226B2 (hr) |
| EP (1) | EP2849747B1 (hr) |
| JP (1) | JP6116678B2 (hr) |
| CN (1) | CN104284660A (hr) |
| AU (1) | AU2013262077B2 (hr) |
| BR (1) | BR112014028566A2 (hr) |
| CA (1) | CA2873867A1 (hr) |
| CY (1) | CY1119781T1 (hr) |
| DK (1) | DK2849747T3 (hr) |
| EA (1) | EA027145B1 (hr) |
| ES (1) | ES2658217T3 (hr) |
| HK (1) | HK1204938A1 (hr) |
| HR (1) | HRP20171725T1 (hr) |
| HU (1) | HUE034658T2 (hr) |
| IL (1) | IL235653B (hr) |
| LT (1) | LT2849747T (hr) |
| MX (1) | MX356493B (hr) |
| NO (1) | NO2849747T3 (hr) |
| PL (1) | PL2849747T3 (hr) |
| PT (1) | PT2849747T (hr) |
| RS (1) | RS56788B1 (hr) |
| SI (1) | SI2849747T1 (hr) |
| WO (1) | WO2013170971A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3247352T3 (da) | 2015-01-23 | 2020-09-07 | Gruenenthal Gmbh | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068838B1 (en) | 1981-06-26 | 1986-09-17 | The Upjohn Company | Analgesic process and composition |
| US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4404208A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and tiflamizole |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| ES2098264T3 (es) | 1989-05-22 | 1997-05-01 | Biochemical Veterinary Res | Sales metalicas divalentes de indometacina. |
| US5472711A (en) | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
| US5330761A (en) | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| EP1219304B1 (de) | 2000-12-28 | 2004-10-20 | Fresenius Kabi Austria GmbH | Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung |
| ES2286177T3 (es) | 2002-06-17 | 2007-12-01 | Chiesi Farmaceutici S.P.A. | Procedimiento para la preparacion de piroxicam: compuestos de inclusion de betaciclodextrina. |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE10257824B4 (de) | 2002-12-10 | 2004-11-11 | Kochem, Hans-Günter, Dr. | Zusammensetzung zur Schmerzbehandlung, insbesondere zur Behandlung von Gelenkschmerzen |
| US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
| US7132452B2 (en) | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| KR20080012976A (ko) * | 2005-06-17 | 2008-02-12 | 화이자 인코포레이티드 | Ｏｒｌ1-수용기 길항제로서의 알파-(아릴- 또는헤테로아릴-메틸)-베타-피페리디노 프로판아마이드 화합물 |
| PT2012763E (pt) * | 2006-04-28 | 2011-04-29 | Gruenenthal Gmbh | Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine |
| CN101147735A (zh) | 2006-09-19 | 2008-03-26 | 沈阳华泰药物研究有限公司 | 注射用药物组合物及其药盒 |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| DE102006056458A1 (de) | 2006-11-28 | 2008-05-29 | Grünenthal GmbH | Arzneimittelzubereitung von Tramadol und Acetaminophen |
| JP5452494B2 (ja) * | 2007-10-09 | 2014-03-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物 |
| CN100560061C (zh) | 2008-06-20 | 2009-11-18 | 海南锦瑞制药股份有限公司 | 一种氯诺昔康冻干粉针剂及其制备方法 |
| PL2735338T3 (pl) * | 2008-09-05 | 2019-07-31 | Grünenthal GmbH | Farmaceutyczne skojarzenie 3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu i pregabaliny lub gabapentyny |
| MX2011002117A (es) * | 2008-09-05 | 2011-03-28 | Gruenenthal Gmbh | Combinacion farmaceutica que comprenden 6-dimetilaminometil-1-(3-m etoxi-fenil)-ciclohexano-1,3-diol y un aines. |
| NZ604662A (en) * | 2010-08-04 | 2014-08-29 | Gruenenthal Gmbh | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine |
| MX354686B (es) * | 2010-08-04 | 2018-03-15 | Gruenenthal Gmbh Star | Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4'.9'-dihidro-3'h-espi ro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico. |
| RU2589831C2 (ru) * | 2010-08-04 | 2016-07-10 | Грюненталь Гмбх | ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН |
-
2013
- 2013-05-13 US US13/892,732 patent/US8912226B2/en active Active
- 2013-05-16 PT PT137250726T patent/PT2849747T/pt unknown
- 2013-05-16 CA CA2873867A patent/CA2873867A1/en not_active Abandoned
- 2013-05-16 CN CN201380025645.4A patent/CN104284660A/zh active Pending
- 2013-05-16 ES ES13725072.6T patent/ES2658217T3/es active Active
- 2013-05-16 JP JP2015511957A patent/JP6116678B2/ja active Active
- 2013-05-16 BR BR112014028566A patent/BR112014028566A2/pt active Search and Examination
- 2013-05-16 RS RS20180063A patent/RS56788B1/sr unknown
- 2013-05-16 WO PCT/EP2013/001470 patent/WO2013170971A1/en active Application Filing
- 2013-05-16 DK DK13725072.6T patent/DK2849747T3/en active
- 2013-05-16 MX MX2014013028A patent/MX356493B/es active IP Right Grant
- 2013-05-16 AU AU2013262077A patent/AU2013262077B2/en not_active Ceased
- 2013-05-16 EP EP13725072.6A patent/EP2849747B1/en active Active
- 2013-05-16 NO NO13725072A patent/NO2849747T3/no unknown
- 2013-05-16 LT LTEP13725072.6T patent/LT2849747T/lt unknown
- 2013-05-16 PL PL13725072T patent/PL2849747T3/pl unknown
- 2013-05-16 EA EA201401270A patent/EA027145B1/ru not_active IP Right Cessation
- 2013-05-16 HU HUE13725072A patent/HUE034658T2/hu unknown
- 2013-05-16 SI SI201330926T patent/SI2849747T1/en unknown
-
2014
- 2014-11-12 IL IL235653A patent/IL235653B/en active IP Right Grant
-
2015
- 2015-06-11 HK HK15105569.3A patent/HK1204938A1/xx not_active IP Right Cessation
-
2017
- 2017-11-10 HR HRP20171725TT patent/HRP20171725T1/hr unknown
-
2018
- 2018-01-16 CY CY20181100051T patent/CY1119781T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2849747T3 (pl) | 2018-03-30 |
| MX2014013028A (es) | 2015-02-04 |
| EA201401270A1 (ru) | 2016-05-31 |
| EP2849747A1 (en) | 2015-03-25 |
| IL235653B (en) | 2018-08-30 |
| ES2658217T3 (es) | 2018-03-08 |
| EA027145B1 (ru) | 2017-06-30 |
| CY1119781T1 (el) | 2018-06-27 |
| DK2849747T3 (en) | 2017-12-04 |
| AU2013262077B2 (en) | 2017-10-26 |
| AU2013262077A1 (en) | 2015-01-22 |
| JP2015516451A (ja) | 2015-06-11 |
| CA2873867A1 (en) | 2013-11-21 |
| SI2849747T1 (en) | 2018-04-30 |
| NO2849747T3 (hr) | 2018-03-31 |
| BR112014028566A2 (pt) | 2017-06-27 |
| JP6116678B2 (ja) | 2017-04-19 |
| EP2849747B1 (en) | 2017-11-01 |
| US20130317075A1 (en) | 2013-11-28 |
| LT2849747T (lt) | 2018-01-25 |
| US8912226B2 (en) | 2014-12-16 |
| CN104284660A (zh) | 2015-01-14 |
| IL235653A0 (en) | 2015-01-29 |
| RS56788B1 (sr) | 2018-04-30 |
| HK1204938A1 (en) | 2015-12-11 |
| WO2013170971A1 (en) | 2013-11-21 |
| HUE034658T2 (hu) | 2018-02-28 |
| MX356493B (es) | 2018-05-31 |
| PT2849747T (pt) | 2018-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171693T1 (hr) | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen | |
| HRP20190500T1 (hr) | Farmaceutska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola i pregabalina ili gabapentina | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| HK1182619A1 (zh) | 用於局部給藥的螺-羥吲哚化合物的藥物組合物及其作為治療劑的用途 | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| JP2015515475A5 (hr) | ||
| CO6630134A2 (es) | Formulación orales y sales lipofílicas de metilnaltrexona | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2009102342A5 (hr) | ||
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| JP2013528600A5 (hr) | ||
| WO2013090278A3 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| HRP20110271T1 (hr) | Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek) | |
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| HRP20140569T1 (hr) | Derivati cis-tetrahidro-spiro(cikloheksan-1,1'-pirido[3,4-b]indol)-4-amina | |
| RU2013110124A (ru) | Комбинированная противораковая терапия | |
| JP2012236834A5 (hr) | ||
| HRP20171708T1 (hr) | FARMACEUTSKI PRIPRAVAK KOJI SADRŽI (1R,4R)-6'-FLUORO-N,N-DIMETIL-4-FENIL-4',9'-DIHIDRO-3'H-SPIRO[CIKLOHEKSAN-1,1'-PIRANO [3,4,b]INDOL]-4-AMIN I GABAPENTINOID | |
| WO2011128407A3 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| RU2014129508A (ru) | Новая комбинация | |
| HRP20170517T1 (hr) | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikoheksan-1,1'-pirano[3,4,b]indol]-4-amin i antikonvulziv | |
| HRP20191322T1 (hr) | Antitumorska kombinacija koja sadži kabazitaksel i cisplatin |